WO2024078468A1 - 二苯乙烯衍生物用于预防和或治疗溃疡的用途 - Google Patents

二苯乙烯衍生物用于预防和或治疗溃疡的用途 Download PDF

Info

Publication number
WO2024078468A1
WO2024078468A1 PCT/CN2023/123650 CN2023123650W WO2024078468A1 WO 2024078468 A1 WO2024078468 A1 WO 2024078468A1 CN 2023123650 W CN2023123650 W CN 2023123650W WO 2024078468 A1 WO2024078468 A1 WO 2024078468A1
Authority
WO
WIPO (PCT)
Prior art keywords
ulcers
oral
ulcer
use according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/123650
Other languages
English (en)
French (fr)
Inventor
贾剑敏
蔡亚仙
马志龙
陈明
欧阳雯雯
竟香艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thederma Shanghai Co Ltd
Original Assignee
Thederma Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thederma Shanghai Co Ltd filed Critical Thederma Shanghai Co Ltd
Priority to AU2023359133A priority Critical patent/AU2023359133A1/en
Priority to CN202380014520.5A priority patent/CN118265525A/zh
Priority to JP2025520721A priority patent/JP2025532421A/ja
Priority to EP23876670.3A priority patent/EP4603085A4/en
Priority to KR1020257013410A priority patent/KR20250069676A/ko
Publication of WO2024078468A1 publication Critical patent/WO2024078468A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Definitions

  • the invention relates to use of stilbene derivatives for preventing and or treating ulcers, and belongs to the field of medicine.
  • Ulcer is a phenomenon of ulceration or loss of human mucous membrane or skin. Clinically, it often occurs in the gastrointestinal tract, oral cavity, genitals and other parts, and the cause is complex.
  • Oral ulcers commonly known as "mouth sores" are a common ulcerative injury disease that occurs in the oral mucosa. They are often seen on the inner side of the lips, tongue, tongue ventral surface, buccal mucosa, vestibule groove, soft palate and other parts. The current incidence rate is relatively high. Oral ulcers include recurrent oral ulcers, traumatic oral ulcers and oral ulcers associated with diseases. Among them, recurrent oral ulcers are also called recurrent aphthous ulcers or frequent oral ulcers.
  • traumatic oral ulcers include oral ulcers caused by mechanical damage (such as damage to the oral mucosa caused by hard objects such as fish bones, sand and gravel in food, toothbrushes, and tartar deposited on the surface of teeth), chemical burns (such as local oral mucosal damage caused by the use of analgesic lozenges such as aspirin, silver nitrate, iodine tincture and other irritating drugs), cold and hot stimulation (such as mucosal burns caused by high water temperature, overly hot food, or mucosal frostbite caused by improper low-temperature treatment); oral ulcers associated with diseases include oral ulcers associated with diseases such as Behcet's disease, Reiter's syndrome, and tumors.
  • oral ulcers are still unclear.
  • Possible inducing factors include genetic factors, dietary factors, immune factors, psychological factors or traumatic factors.
  • the drug treatment of oral ulcers is preferentially local treatment, including the use of analgesics (such as lidocaine, benzocaine, benzydamine), anti-inflammatory drugs (such as chlorhexidine, iodine), healing-promoting drugs (such as Bingpengsan, Xiguashuang, recombinant human epidermis, etc.).
  • analgesics such as lidocaine, benzocaine, benzydamine
  • anti-inflammatory drugs such as chlorhexidine, iodine
  • healing-promoting drugs such as Bingpengsan, Xiguashuang, recombinant human epidermis, etc.
  • systemic administration can be used, including the use of immune preparations or vitamins.
  • the present invention provides the use of at least one compound selected from the following formula (I) and its pharmaceutically acceptable salt for preparing a medicament, wherein the medicament is used for preventing and/or treating ulcers:
  • the drug is a pharmaceutical composition.
  • the pharmaceutical composition comprises at least one of the compound represented by formula (I) described above and a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical composition, comprising at least one of the compounds represented by formula (I) and pharmaceutically acceptable salts thereof, wherein the pharmaceutical composition is used for preventing and/or treating ulcers.
  • the pharmaceutical composition comprises a therapeutically effective amount of at least one of the compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
  • the present invention also provides the use of the compound represented by formula (I), the pharmaceutically acceptable salt of the compound represented by formula (I), the drug or the pharmaceutical composition for preventing and/or treating ulcers.
  • the present invention also provides the compound represented by formula (I), the pharmaceutically acceptable salt of the compound represented by formula (I), the drug or the pharmaceutical composition for preventing and/or treating ulcer.
  • the present invention also provides a method for preventing and/or treating ulcers, comprising administering to a patient an effective amount or a therapeutically effective amount of at least one of the compounds represented by formula (I) and pharmaceutically acceptable salts thereof.
  • the ulcer can be selected from pressure ulcer (Pressure ulcer, also known as bedsore), genital ulcer (Genital ulcer), ulcerative dermatitis (Ulcerative dermatitis), anal ulcer, One or more of rectal ulcer, foot ulcer, diabetic foot ulcer, corneal ulcer, oral ulcer, aphthous ulcer, peptic ulcer, venous ulcer, stress ulcer, ulcer located in the stomach and proximal duodenum, ulcerative sarcoidosis, ulcerative lichen planus, ulcerative colitis, and ulcer tendency.
  • Pressure ulcer Pressure ulcer, also known as bedsore
  • Genital ulcer genital ulcer
  • ulcerative dermatitis Ulcerative dermatitis
  • anal ulcer One or more of rectal ulcer, foot ulcer, diabetic foot ulcer, corneal ulcer, oral ulcer, aphthous ulcer, peptic ulcer, venous ulcer, stress ulcer, ulcer located in the stomach and proximal duodenum, ulcerative sarcoidosis, ulcerative lichen planus, ulcerative colitis
  • the oral ulcer is selected from recurrent oral ulcer, traumatic oral ulcer and oral ulcer associated with or caused by disease.
  • the recurrent oral ulcer is also called recurrent aphthous ulcer or frequent oral ulcer.
  • the traumatic oral ulcers include oral ulcers caused by mechanical damage (such as damage to the oral mucosa caused by hard objects such as fish bones, sand and gravel in food, toothbrushes, tartar deposited on the surface of teeth, etc.), chemical burns (such as local oral mucosal damage caused by the use of analgesic lozenges such as aspirin, silver nitrate, iodine tincture and other irritating drugs), cold and hot stimulation (such as mucosal burns caused by excessively high water temperature, overly hot food, etc., or mucosal frostbite caused by improper low-temperature treatment).
  • mechanical damage such as damage to the oral mucosa caused by hard objects such as fish bones, sand and gravel in food, toothbrushes, tartar deposited on the surface of teeth, etc.
  • chemical burns such as local oral mucosal damage caused by the use of analgesic lozenges such as aspirin, silver nitrate, iodine tincture and other irritating drugs
  • the oral ulcers associated with or caused by the diseases include oral ulcers associated with or caused by diseases such as Behcet's disease, Reiter's syndrome, tumors, etc.
  • the medicament is used for preventing and/or treating at least one of recurrent oral ulcers and traumatic oral ulcers.
  • the compound represented by formula (I) may be an E-type or Z-type isomer, preferably an E-type isomer represented by the following formula (I-1):
  • the compound represented by formula (I) is benvimod.
  • the pharmaceutically acceptable salt may be selected from addition salts of the compound of formula (I) and a pharmaceutically acceptable base.
  • the drug or pharmaceutical composition contains only the compound represented by formula (I) as the active ingredient, and more preferably contains only the E-type isomer represented by formula (I-1) as the active ingredient.
  • the daily dosage of the drug or pharmaceutical composition is a therapeutically effective amount, such as 0.01 to 1 mg/kg/d, such as 0.02 to 0.4 mg/kg/d, exemplified by 0.05 mg/kg/d, 0.06 mg/kg/d, 0.07 mg/kg/d, 0.08 mg/kg/d, 0.09 mg/kg/d, 0.1 mg/kg/d, 0.12 mg/kg/d, 0.15 mg/kg/d, 0.2 mg/kg/d, 0.3 mg/kg/d, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg/d, 0.7 mg/kg/d, 0.8 mg/kg/d, 0.9 mg/kg/d, and 1 mg/kg/d.
  • the drug or pharmaceutical composition is preferably a pharmaceutical preparation. More preferably, the pharmaceutical composition is a single-dose preparation, wherein the content of the compound represented by formula (I) and its pharmaceutically acceptable salt calculated as the compound represented by formula (I) in the single-dose preparation is a therapeutically effective amount, for example, 1 to 10 mg, such as 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg.
  • the single-dose formulation refers to a unit-dose formulation, wherein the compound of formula (I) or a salt thereof is loaded in 1 unit package.
  • the drug or pharmaceutical composition may further include a pharmaceutically acceptable excipient, such as a carrier or excipient.
  • a pharmaceutically acceptable excipient is preferably chemically non-reactive or inert to the active ingredient.
  • the pharmaceutically acceptable excipient is selected from at least one of the following excipients, including but not limited to: a filler, a disintegrant, a binder, a lubricant, a surfactant, a flavoring agent, a wetting agent, a matrix, etc.
  • the administration route of the drug or pharmaceutical composition includes but is not limited to gastrointestinal administration or parenteral administration; wherein the gastrointestinal administration may be oral administration; the parenteral administration may be topical administration, transdermal administration, injection, etc.
  • the administration route of the drug or pharmaceutical composition can be a combination of topical administration and oral administration.
  • the dosage form of the drug or pharmaceutical composition can be selected from capsules, Tablet, patch, film, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol, ointment, cream, suppository, or injection.
  • an effective amount refers to an amount of the compound of the present invention sufficient to achieve the intended application (including but not limited to the treatment of diseases as defined below).
  • the therapeutically effective amount may vary depending on the intended application (in vitro or in vivo), or the subject and disease condition to be treated, such as the weight and age of the subject, the severity of the disease condition, and the mode of administration, which can be easily determined by a person of ordinary skill in the art.
  • the specific dosage will vary depending on the following factors: the specific compound selected, the dosage regimen relied on, whether it is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system carried.
  • patient refers to a mammal suffering from or at risk of suffering from said ulcer, for example selected from rodents, cows, pigs, dogs, cats and primates, in particular humans.
  • the present invention unexpectedly found that the compound of formula (I) or a pharmaceutically acceptable salt thereof can effectively prevent or treat ulcers, and has excellent therapeutic effect on oral ulcers.
  • the drug used in the following experiments is a 1% benvimod cream, which contains 1% benvimod by mass, as well as mometasone furoate, propylene glycol, white vaseline, light liquid paraffin, cetyl alcohol, glyceryl monostearate, purified water, ethylparaben, etc.
  • Dosage method squeeze out a small amount of the above cream and apply it on a cotton swab, apply it to the ulcer surface after three meals and before going to bed after oral hygiene cleaning, and cover it 4 times a day, and continue to use the medicine until the ulcer heals. Do not use other drugs during the administration period.
  • Subject 1 Suffering from non-recurrent oral ulcers, multiple ulcers in the mouth, about 0.3x0.6cm, and a course of about 10 days, without taking other drugs. The pain was significantly relieved on the first day of applying the medicine, the ulcers were significantly improved on the second day, and all the ulcers healed and disappeared on the fourth day.
  • Subject 2 Suffering from recurrent oral ulcers, multiple ulcers in the mouth, about 0.3x0.7cm, and a course of about 6 days, without taking other medications. The pain was significantly relieved on the first day of applying the medication, and all ulcers healed and disappeared on the third day.
  • Example 2 Efficacy of 7-day treatment of oral ulcer model in SD male rats
  • Example 3 Efficacy of 10-day treatment of DB/DB male mouse diabetic foot ulcer model
  • mice Eighteen DB/DB male mice were randomly divided into three groups, namely, the model group (propylene glycol solvent group), the 2% indigo group (1 mg/mouse) and the 2% bevimod group (1 mg/mouse).
  • the model group propylene glycol solvent group
  • the 2% indigo group (1 mg/mouse)
  • the 2% bevimod group (1 mg/mouse).
  • Foot ulcer modeling After the mouse was anesthetized, the foot was disinfected, and a 4mm*5mm rectangular area was marked on the dorsum of the foot, and the skin and fascia within the range were removed.
  • Drug administration 50ul of each solution was taken from the dorsum of the mouse foot with a pipette and evenly applied to the ulcer site, twice a day for 10 consecutive days, and the length and width of the ulcer were recorded.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及二苯乙烯衍生物用于预防和或治疗溃疡的用途。式(I)化合物或其药学上可接受的盐可以有效地预防或治疗溃疡，特别是对口腔溃疡有疗效

Description

二苯乙烯衍生物用于预防和或治疗溃疡的用途
本申请要求2022年10月10日向中国国家知识产权局提交的，专利申请号为202211236827.3，发明名称为“二苯乙烯衍生物用于预防和或治疗溃疡的用途”申请的全文通过引用的方式结合于本申请中。
技术领域
本发明涉及二苯乙烯衍生物用于预防和或治疗溃疡的用途，属于医药领域。
背景技术
溃疡是人体的黏膜或者皮肤的溃烂或者缺失的现象，临床上多发于胃肠道、口腔、生殖器等部位，病因复杂。
口腔溃疡俗称“口疮”，是一种常见的发生于口腔黏膜的溃疡性损伤病症，多见于唇内侧、舌头、舌腹、颊黏膜、前庭沟、软腭等部位，目前发病率较高。口腔溃疡包括复发性口腔溃疡、创伤性口腔溃疡和疾病伴发的口腔溃疡。其中，复发性口腔溃疡又称为复发性阿弗他溃疡或经常性口腔溃疡。我国2012年发布的《复发性阿弗他溃疡诊疗指南》指出，10％～25％的人群患有复发性口腔溃疡，好发年龄为10～30岁；创伤性口腔溃疡包括机械性损伤(如因食物中的鱼骨、砂石等硬物、牙刷、牙齿表面沉积的牙结石等造成口腔黏膜损伤)、化学性灼伤(如使用阿司匹林等镇痛口含片、硝酸银、碘酊等刺激性药物造成的局部口腔黏膜损伤)、冷热刺激(如因水温过高、食物过烫等引起的黏膜灼伤或因低温治疗操作不当引起的黏膜冻伤)导致的口腔溃疡；疾病伴发的口腔溃疡则包括如白塞病、莱特尔综合征、肿瘤等疾病伴发的口腔溃疡。
目前，口腔溃疡的致病原因尚不明确，其可能的诱发因素包括遗传因素、饮食因素、免疫因素、精神因素或创伤性因素等。对口腔溃疡的药物治疗优先选择局部治疗，包括使用止痛药物(如利多卡因、苯佐卡因、苄达明)、消炎药物(如氯己定、西地碘)、促进愈合药物(如冰硼散、西瓜霜、重组人表皮 生长因子)及康复新液等药物。对于口腔溃疡的重症或复发频率高的患者，可应用全身给药，包括使用免疫制剂或维生素等。
目前，仍需开发对于溃疡，尤其是口腔溃疡具有良好疗效的新药物。发明内容
为了改善上述技术问题，本发明提供选自如下式(I)所示的化合物及其药学上可接受的盐中的至少一种用于制备药物的用途，其中所述药物用于预防和/或治疗溃疡：
根据本发明的实施方案，所述药物为药物组合物。优选地，所述药物组合物包含上文所述的式(I)所示的化合物及其药学上可接受的盐中的至少一种。
本发明还提供一种药物组合物，所述药物组合物包含上文所述的式(I)所示的化合物及其药学上可接受的盐中的至少一种，其中所述药物组合物用于预防和/或治疗溃疡。
根据本发明的实施方案，所述药物组合物包含治疗有效量的所述的式(I)所示的化合物及其药学上可接受的盐中的至少一种。
本发明还提供所述式(I)所示的化合物、式(I)所示的化合物的药学上可接受的盐、所述药物或所述药物组合物的用途，其用于预防和/或治疗溃疡。
本发明还提供用于预防和/或治疗溃疡的所述式(I)所示的化合物、式(I)所示的化合物的药学上可接受的盐、所述药物或所述药物组合物。
本发明还提供一种预防和/或治疗溃疡的方法，所述方法包括向患者给予有效量或治疗有效量的上文所述的式(I)所示的化合物及其药学上可接受的盐中的至少一种。
根据本发明的实施方案，所述溃疡可以选自压疮(Pressure ulcer，也称褥疮)、生殖器溃疡(Genital ulcer)、溃疡性皮炎(Ulcerative dermatitis)、肛门溃疡、 直肠溃疡、足部溃疡、糖尿病足溃疡、角膜溃疡(Corneal ulcer)、口腔溃疡、口疮(Aphthous ulcer，也称为溃疡疮)、消化性溃疡(Peptic ulcer)、静脉溃疡(Venous ulcer)、应激性溃疡(Stress ulcer，位于胃和十二指肠近端的溃疡)、溃疡性结节病(Ulcerative sarcoidosis)、溃疡性扁平苔藓(Ulcerative lichen planus)、溃疡性结肠炎(Ulcerative colitis)、溃疡倾向(Ulcerative disposition)中的一种或多种。
根据本发明的实施方案，所述口腔溃疡选自复发性口腔溃疡、创伤性口腔溃疡和疾病伴发或导致的口腔溃疡。
根据本说明书的上下文，所述复发性口腔溃疡又称为复发性阿弗他溃疡或经常性口腔溃疡。
根据本发明的实施方案，所述创伤性口腔溃疡包括机械性损伤(如因食物中的鱼骨、砂石等硬物、牙刷、牙齿表面沉积的牙结石等造成口腔黏膜损伤)、化学性灼伤(如使用阿司匹林等镇痛口含片、硝酸银、碘酊等刺激性药物造成的局部口腔黏膜损伤)、冷热刺激(如因水温过高、食物过烫等引起的黏膜灼伤或因低温治疗操作不当引起的黏膜冻伤)导致的口腔溃疡。
根据本发明的实施方案，所述疾病伴发或导致的口腔溃疡则包括如白塞病、莱特尔综合征、肿瘤等疾病伴发或导致的口腔溃疡。
根据本发明示例性的实施方案，所述药物用于预防和/或治疗复发性口腔溃疡和创伤性口腔溃疡中的至少一种。
根据本发明的实施方案，所述式(I)所示的化合物可以为E型或Z型异构体，优选下式(I-1)所示的E型异构体：
根据本发明的优选实施方案，式(I)所示的化合物为本维莫德。
根据本发明的实施方案，所述药学上可接受的盐可以选自式(I)化合物与药学上可接受的碱的加成盐。
优选地，所述药物或药物组合物中，仅以式(I)所示的化合物作为活性成分，还优选仅以式(I-1)所示的E型异构体作为活性成分。
根据本发明的实施方案，以式(I)化合物计，所述药物或药物组合物的给药日剂量为治疗有效量的，如0.01～1mg/kg/d，比如0.02～0.4mg/kg/d，示例性为0.05mg/kg/d、0.06mg/kg/d、0.07mg/kg/d、0.08mg/kg/d、0.09mg/kg/d、0.1mg/kg/d、0.12mg/kg/d、0.15mg/kg/d、0.2mg/kg/d、0.3mg/kg/d、0.4mg/kg、0.5mg/kg、0.6mg/kg/d、0.7mg/kg/d、0.8mg/kg/d、0.9mg/kg/d、1mg/kg/d。
根据本发明的实施方案，所述药物或药物组合物优选为药物制剂。更优选地，所述药物组合物为单剂量制剂，其中所述单剂量制剂中，以式(I)所示化合物计的式(I)所示的化合物及其药学上可接受的盐含量为治疗有效量的，例如1～10mg，如1mg、2mg、3mg、4mg、5mg、6mg、7mg、8mg、9mg、10mg。
根据本发明的实施方案，所述单剂量制剂是指单位剂量制剂，其中所述式(I)化合物或其盐装载于1个单元包装之内。
根据本发明的实施方案，所述药物或药物组合物还可以包含药学上可接受的辅料，如载体或赋形剂。所述药学上可接受的辅料优选为对活性成分无化学反应性或呈惰性的。例如，所述药学上可接受的辅料选自包括但不限于下列辅料中的至少一种：填充剂、崩解剂、粘合剂、润滑剂、表面活性剂、矫味剂、湿润剂、基质等。
根据本发明的实施方案，所述药物或药物组合物的给药途径包括但不限于胃肠道给药或非胃肠道给药；其中，所述胃肠道给药可以为口服给药；所述非胃肠道给药可以为局部给药、经皮给药、注射给药等。
在一种实施方案中，所述药物或药物组合物的给药途径可以局部给药与口服给药相配合。
根据本发明的实施方案，所述药物或药物组合物的剂型可以选自胶囊剂、 片剂、贴剂、膜剂、丸剂、散剂、锭剂、小药囊、扁囊剂、酏剂、混悬剂、乳剂、溶液剂、糖浆剂、气雾剂、软膏剂、乳膏剂、栓剂或注射剂。
术语定义和说明
除非另有说明，本申请说明书和权利要求书中记载的术语定义，包括其作为实例的定义、示例性的定义、优选的定义、表格中记载的定义、实施例中具体化合物的定义等，可以彼此之间任意组合和结合。这样的组合和结合应当属于本申请说明书记载的范围内。
术语“有效量”或者“治疗有效量”是指足以实现预期应用(包括但不限于如下定义的疾病治疗)的本发明所述化合物的量。治疗有效量可以取决于以下因素而改变：预期应用(体外或者体内)，或者所治疗的受试者和疾病病症如受试者的重量和年龄、疾病病症的严重性和给药方式等，其可以由本领域普通技术人员容易地确定。具体剂量将取决于以下因素而改变：所选择的特定化合物、所依据的给药方案、是否与其它化合物组合给药、给药的时间安排、所给药的组织和所承载的物理递送系统。
术语“患者”是指遭受所述溃疡或存在患有所述溃疡风险的哺乳动物，例如选自啮齿类、牛、猪、狗、猫和灵长类动物，特别是人。
有益效果
本发明出人预料地发现，式(I)化合物或其药学上可接受的盐可以有效地预防或治疗溃疡，特别是对口腔溃疡有优异的疗效。
具体实施方式
下文将结合具体实施例对本发明的技术方案做更进一步的详细说明。应当理解，下列实施例仅为示例性地说明和解释本发明，而不应被解释为对本发明保护范围的限制。凡基于本发明上述内容所实现的技术均涵盖在本发明旨在保 护的范围内。
除非另有说明，以下实施例中使用的原料和试剂均为市售商品，或者可以通过已知方法制备。
实施例1口腔溃疡疗效实验
下列实验中选用的药物为本维莫德含量为1％的乳膏，其中含质量百分比含量为1％的本维莫德，以及糠酸莫米松、丙二醇、白凡士林、轻质液体石蜡、十六醇、单硬脂酸甘油酯、纯化水、羟苯乙酯等。
给药方法：挤出上述乳膏少量涂于棉棒上，于三餐后、睡前口腔卫生清洁后涂于并覆盖溃疡表面，一日4次，持续用药至溃疡愈合。在给药期间不使用其他药物。
受试者1：患有非复发性口腔溃疡，口腔内溃疡多处，约0.3x0.6cm,病程约10天，未用其它药物。涂药第1天痛感明显减轻，2天溃疡明显改善第4天溃疡全部愈合消失。
受试者2：患有复发性口腔溃疡，口腔内溃疡多处，约0.3x0.7cm,病程约6天，未用其它药物。涂药第1天痛感明显减轻，第3天溃疡全部愈合消失。
实施例2：SD雄性大鼠口腔溃疡模型治疗7天的药效
将18只SD雄性大鼠随机分成3组，即模型组(丙二醇溶媒组)，2％靛蓝组(1mg/只)，2％本维莫德组(1mg/只)。口腔溃疡造模：在大鼠下切牙牙槽骨唇侧黏膜处放置1cm*0.6cm的滤纸(浸润至60％冰醋酸溶液)维持1min。给药：大鼠麻醉后，用移液枪吸取50ul各组溶液均匀涂抹至溃疡部位，每天2次，连续给药7天。实验结果如表1，各组经冰醋酸处理后，均出现假膜覆盖，中央凹陷，边缘红肿，刺激后疼痛反应明细等症状，给药结束后，各种症状有所缓解。2％本维莫德有好的治疗效果，并且其药效优于2％靛蓝。
表1 SD雄性大鼠口腔溃疡模型治疗7天的药效(n＝6)

注:溃疡愈合率＝(Day0溃疡面积-Day10溃疡面积)/Day0溃疡面积*100％
实施例3：DB/DB雄性小鼠糖尿病足溃疡模型治疗10天的药效
18只DB/DB雄性小鼠随机分成3组即模型组(丙二醇溶媒组)，2％靛蓝组(1mg/只)2％本维莫德组(1mg/)只。
足溃疡造模:小鼠麻醉后，足部消毒，在足背部标记4mm*5mm的矩形区域，剔除范围内皮肤和筋膜。
给药:在小鼠足背部用移液枪吸取50ul各组溶液均匀涂抹至溃疡部位，每天2次，连续给药10天，记录溃疡的长和宽。
实验结果如表2，各组经处理后，足部红肿，伤口周围出现溃烂，疼痛反映明显，小鼠出现所缩爪行为，经过10天给药后，2％本维莫德具有明显的抑制效果，且结果优于2％靛蓝组。
表2 DB/DB雄性小鼠糖尿病足溃疡模型治疗10天的药效(n＝6)

注:溃疡愈合率＝(Day0溃疡面积-Day10溃疡面积)/Day0溃疡面积*100％
采用one-way ANOVA进行统计分析，与vehicle组比，**表示p＜0.05
以上对本发明技术方案的实施方式进行了示例性的说明。应当理解，本发 明的保护范围不拘囿于上述实施方式。凡在本发明的精神和原则之内，本领域技术人员所做的任何修改、等同替换、改进等，均应包含在本申请权利要求书的保护范围之内。

Claims (9)

  1. 如下式(I)所示化合物及其药学上可接受的盐中的至少一种用于制备药物的用途，其中所述药物用于预防和/或治疗溃疡：
  2. 根据权利要求1所述的用途，其中所述药物为药物组合物；
    优选地，所述药物组合物包含上文所述的式(I)所示的化合物及其药学上可接受的盐中的至少一种；
    更优选地，所述药物组合物包含治疗有效量的所述的式(I)所示的化合物及其药学上可接受的盐中的至少一种。
  3. 根据权利要求1或2所述的用途，其中所述式(I)所示的化合物为E型或Z型异构体，优选下式(I-1)所示的E型异构体：
  4. 根据权利要求1-3任一项所述的用途，其中所述溃疡选自压疮、生殖器溃疡、溃疡性皮炎、肛门溃疡、直肠溃疡、足部溃疡、糖尿病足溃疡、角膜溃疡、口腔溃疡、口疮、消化性溃疡、静脉溃疡、应激性溃疡、溃疡性结节病、溃疡性扁平苔藓、溃疡性结肠炎、溃疡倾向中的一种或多种。
  5. 根据权利要求4所述的用途，其中所述口腔溃疡选自复发性口腔溃疡、创 伤性口腔溃疡和疾病伴发或导致的口腔溃疡。
  6. 根据权利要求5所述的用途，其中所述复发性口腔溃疡选自复发性阿弗他溃疡或经常性口腔溃疡。
  7. 根据权利要求5所述的用途，其中所述创伤性口腔溃疡包括机械性损伤、化学性灼伤、冷热刺激导致的口腔溃疡。
  8. 根据权利要求5所述的用途，其中所述疾病伴发或导致的口腔溃疡则包括白塞病、莱特尔综合征、肿瘤等疾病伴发或导致的口腔溃疡。
  9. 根据权利要求5所述的用途，其中所述口腔溃疡选自复发性口腔溃疡和创伤性口腔溃疡中的至少一种。根据权利要求1-9任一项所述的用途，其中所述药物为单剂量制剂；优选地，所述单剂量制剂中，以式(I)所示化合物计的式(I)所示的化合物及其药学上可接受的盐含量为治疗有效量的，例如1～10mg。
PCT/CN2023/123650 2022-10-10 2023-10-10 二苯乙烯衍生物用于预防和或治疗溃疡的用途 Ceased WO2024078468A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2023359133A AU2023359133A1 (en) 2022-10-10 2023-10-10 Use of stilbene derivative in prevention and/or treatment of ulcers
CN202380014520.5A CN118265525A (zh) 2022-10-10 2023-10-10 二苯乙烯衍生物用于预防和/或治疗溃疡的用途
JP2025520721A JP2025532421A (ja) 2022-10-10 2023-10-10 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用
EP23876670.3A EP4603085A4 (en) 2022-10-10 2023-10-10 USE OF A STILBENE DERIVATIVE IN THE PREVENTION AND/OR TREATMENT OF ULCERS
KR1020257013410A KR20250069676A (ko) 2022-10-10 2023-10-10 궤양 예방 및/또는 치료를 위한 스틸벤 유도체의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211236827.3 2022-10-10
CN202211236827 2022-10-10

Publications (1)

Publication Number Publication Date
WO2024078468A1 true WO2024078468A1 (zh) 2024-04-18

Family

ID=90668785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/123650 Ceased WO2024078468A1 (zh) 2022-10-10 2023-10-10 二苯乙烯衍生物用于预防和或治疗溃疡的用途

Country Status (6)

Country Link
EP (1) EP4603085A4 (zh)
JP (1) JP2025532421A (zh)
KR (1) KR20250069676A (zh)
CN (1) CN118265525A (zh)
AU (1) AU2023359133A1 (zh)
WO (1) WO2024078468A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092809A1 (zh) * 2023-11-02 2025-05-08 上海泽德曼医药科技有限公司 稳定性改善的苯酚衍生物的药物组合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111148729A (zh) * 2017-09-30 2020-05-12 北京文丰天济医药科技有限公司 苯烯莫德的晶型及其用途与制备方法
WO2020212982A1 (en) * 2019-04-17 2020-10-22 Sol-Gel Technologies Ltd. Treatment of gastrointestinal disorders with rectal tapinarof compositions
US20200390724A1 (en) * 2019-06-17 2020-12-17 Sol-Gel Technologies Ltd. Treatment of ocular diseases with ophthalmic tapinarof compositions
CN114206315A (zh) * 2019-07-24 2022-03-18 索尔-格尔科技有限公司 用局部他匹那洛夫-egfr抑制剂组合物治疗皮肤病
CN114206312A (zh) * 2019-04-17 2022-03-18 阿佐拉治疗股份有限公司 用于治疗炎性皮肤病的局部组合物和方法
CN114569586A (zh) * 2022-01-28 2022-06-03 鲁奕诗 苯烯莫德灌肠液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170141705A (ko) * 2015-04-08 2017-12-26 바이오멘딕스, 엘엘씨 상처 치유를 조절하기 위한 제형 및 방법
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
US20200345645A1 (en) * 2019-05-03 2020-11-05 Azora Therapeutics, Inc. Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US20240315985A1 (en) * 2021-02-17 2024-09-26 Dermavant Sciences GmbH Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111148729A (zh) * 2017-09-30 2020-05-12 北京文丰天济医药科技有限公司 苯烯莫德的晶型及其用途与制备方法
WO2020212982A1 (en) * 2019-04-17 2020-10-22 Sol-Gel Technologies Ltd. Treatment of gastrointestinal disorders with rectal tapinarof compositions
CN114206312A (zh) * 2019-04-17 2022-03-18 阿佐拉治疗股份有限公司 用于治疗炎性皮肤病的局部组合物和方法
US20200390724A1 (en) * 2019-06-17 2020-12-17 Sol-Gel Technologies Ltd. Treatment of ocular diseases with ophthalmic tapinarof compositions
CN114206315A (zh) * 2019-07-24 2022-03-18 索尔-格尔科技有限公司 用局部他匹那洛夫-egfr抑制剂组合物治疗皮肤病
CN114569586A (zh) * 2022-01-28 2022-06-03 鲁奕诗 苯烯莫德灌肠液及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4603085A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092809A1 (zh) * 2023-11-02 2025-05-08 上海泽德曼医药科技有限公司 稳定性改善的苯酚衍生物的药物组合物及其用途

Also Published As

Publication number Publication date
CN118265525A (zh) 2024-06-28
AU2023359133A1 (en) 2025-04-24
EP4603085A1 (en) 2025-08-20
KR20250069676A (ko) 2025-05-19
EP4603085A4 (en) 2025-12-31
JP2025532421A (ja) 2025-09-29

Similar Documents

Publication Publication Date Title
JP5973411B2 (ja) 医薬組成物
TW200815048A (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US5977087A (en) Topical preparation for treatment of aphthous ulcers and other lesions
Gupta The efficacy of Euphorbia prostrata in early grades of symptomatic hemorrhoids–a pilot study.
JP5828609B2 (ja) 持続性解熱鎮痛消炎剤
JP5542309B2 (ja) 経口医薬組成物
AU2025202935A1 (en) Composition and method for prevention and treatment of cutaneous radiation injury
WO2024078468A1 (zh) 二苯乙烯衍生物用于预防和或治疗溃疡的用途
EP3525767B1 (en) Topical formulations and treatments
CN112007006B (zh) 一种治疗口腔溃疡的药用组合物及其制备方法
HK40123007A (zh) 二苯乙烯衍生物用於预防和或治疗溃疡的用途
CN100594911C (zh) 一种药物组合物及其用途
KR20150048890A (ko) 플루르비프로펜을 포함하는 약학적 조성물
KR20240065134A (ko) 피부 방사선 손상의 예방 및 치료를 위한 조성물 및 방법
CN103041046B (zh) 广东紫珠及其提取物在制备抗消化性溃疡药物中的应用
CN115400112A (zh) L-茶氨酸在制备用于治疗皮肤病的制剂中的应用
CN112933091B (zh) 一种抗胃酸类疾病的药物组合物及应用
CN1076195C (zh) 含有锌化合物和对乙酰氨基苯乙酸的组合物
JP2025533533A (ja) 皮膚放射線障害の予防及び治療のための組成物及び方法
CN120983429A (zh) Pde4d抑制剂在制备治疗或预防口腔溃疡的药物上的应用
JP4993998B2 (ja) イブプロフェンを含有する医薬組成物
WO2024236533A1 (en) Rutin, also named oxerutin, for the treatment of epidermolysis bullosa
JPWO2005058878A1 (ja) 月経困難症の予防および／または治療剤
CN117298071A (zh) 一种用于治疗口腔溃疡的口腔贴膜及其制备方法
CN116570641A (zh) 沙蒿籽用于制备治疗猪口腔烫伤引起流涎的药物的应用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202380014520.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23876670

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025520721

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: AU2023359133

Country of ref document: AU

Ref document number: 2025520721

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20257013410

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020257013410

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2023359133

Country of ref document: AU

Date of ref document: 20231010

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023876670

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023876670

Country of ref document: EP

Effective date: 20250512

WWP Wipo information: published in national office

Ref document number: 1020257013410

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023876670

Country of ref document: EP